Strata Critical Medical Management Commentary: Clinical Acquisitions, Growth Drive Q3 2026 Revenue Up 50.3%
Bitget2026/11/03 12:17- Strata Critical Medical management's commentary attributed third-quarter 2026 revenue growth of 50.3% to $74.1 million primarily to Clinical acquisitions and growth.
- Adjusted EBITDA rose to $9.6 million from $4.2 million a year earlier, supported by Clinical growth, improved Logistics margins and overhead control.
- Logistics revenue fell 3.5% year over year as shorter industry trip distances and reduced flying by a nonexclusive customer weighed on performance.
- Management attributed the $7.6 million net loss from continuing operations entirely to noncash, transaction-related charges, including intangible asset amortization.
- Free cash flow reached a record $8.6 million, benefiting from low aircraft maintenance spending that limited capital expenditures to $0.8 million.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Barrick’s Marquee gold project faces hazy study timing
Japanese and South Korean stock markets open
Marvell Technology (MRVL.US) $115 billion "merger of the century" faces lukewarm reception! Stock has dropped over 40%, experts estimate only a 50% chance of completion
Marvell plans to acquire Lamington for 115 billions USD to strengthen its position in AI, but the probability of completion is only 50%. The two stocks have dropped by nearly 40% and about 35% respectively, with Chinese regulatory approval being the biggest uncertainty.
Crypto prices
More
